Chulalongkorn University’s COVID mRNA vaccine to enter human trials

13 Sept 08:18 Key points summarised by AI

Chulalongkorn University's ChulaCov19, Thailand's first mRNA vaccine, seeks TFDA approval to begin human trials.
Initial development in the US demonstrated the vaccine's safety and superior immune response compared to Pfizer's mRNA vaccine.
Local production by BioNet-Asia is underway, with potential registration by year-end if human trials prove successful.
The university is also developing a second-generation mRNA vaccine for the Omicron variant and a tobacco-plant derived vaccine.

Speculation growing over merger between Bhumjaithai and Kla Tham parties

Today 16:46 Key points summarised by AI

A dinner between Bhumjaithai and Kla Tham party leaders sparked rumors of a potential merger, though Bhumjaithai's leader, Anutin, downplayed it as a casual meal.
The meeting is widely interpreted as a strategic message from Bhumjaithai to the Pheu Thai party, signaling alternative support ahead of an upcoming no-confidence debate.
Thailand's Constitution (Section 99) currently prohibits direct mergers of parties with sitting MPs during the House's term, a rule designed to prevent the 'buying and selling' of MPs.
While direct mergers are restricted, MPs can still switch parties if dismissed by a three-fourths party vote or if their party dissolves, allowing for indirect political realignments.
Kla Tham's voting behavior in the censure debate will demonstrate its loyalty to the government, potentially influencing future political dynamics despite current merger restrictions.